Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant (AMR) infections …

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the
development of several novel β-lactam–β-lactamase inhibitor combinations (BLBLIs). In this …

Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant infections. The …

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa
isolates are frequent causes of serious nosocomial infections that may compromise the …

In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …

As shifts in the epidemiology of β-lactamase-mediated resistance continue, carbapenem-
resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa …

One of the most striking features of Pseudomonas aeruginosa is its outstanding capacity for
developing antimicrobial resistance to nearly all available antipseudomonal agents through …

The management of carbapenem-resistant infections is often based on polymyxins,
tigecycline, aminoglycosides and their combinations. However, in a recent systematic …

As a class, the b-lactams are the most commonly prescribed and clinically dependable
antimicrobials in the United States, representing more than 65% of injected antibiotic …

Carbapenem resistance is a major global health problem that seriously compromises the
treatment of infections caused by nosocomial pathogens. Resistance to carbapenems …